NCT07006532 Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
| NCT ID | NCT07006532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Condition | Kidney Transplant Rejection |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent 2. eGFR\> 25 cc/min 3. Chronicity index \<8 4. IFTA\<40% 5. EBV IgG positive Exclusion Criteria: 1. Active or recurrent infections 2. History of malignancy, unless in remission for more than 2 years with no relapse 3. abnormal liver function tests 4. Platelet \< 100,000
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07006532 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07006532 currently recruiting?
Yes, NCT07006532 is actively recruiting participants. Contact the research team at dr.nooshindalili@gmail.com for enrollment information.
Where is the NCT07006532 trial being conducted?
This trial is being conducted at Tehran, Iran.
Who is sponsoring the NCT07006532 clinical trial?
NCT07006532 is sponsored by Shahid Beheshti University of Medical Sciences. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.